Cover Image
市場調查報告書

Paclitaxel的中國市場分析

Investigation Report on China Paclitaxel Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333628
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Paclitaxel的中國市場分析 Investigation Report on China Paclitaxel Market, 2010-2019
出版日期: 2015年06月25日 內容資訊: 英文 40 Pages
簡介

Paclitaxel當初開發、認證為進行性的非小細胞癌、卵巢癌的治療藥,不過,現在活用於其他各種癌症、腫瘤的治療。在中國,癌症患者年度發現500∼600萬人,而且隨之Paclitaxel市場也擴大了,不過,另一方面,治療單價高成為了市場成長的阻礙因素。儘管如此,2005年達4億人民幣的銷售額,以17.3%年複合成長率(CAGR) 增加,2014年達13億8800萬人民幣。

本報告提供中國的Paclitaxel的市場相關分析、整體市場規模趨勢(過去5年份)和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Paclitaxel的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Paclitaxel市場概況

  • 中國國內的Paclitaxel的專利申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Paclitaxel銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Paclitaxel市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Paclitaxel市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Paclitaxel的醫院用標準價格

  • Abraxis BioScience, LLC (美國) (商標名:Abraxane)
  • Hospira Australia Pty Ltd (澳洲) (商標名:Anzatax)
  • Wellso Pharmaceutical Co., Ltd
  • Bejing Union Pharmaceutical Co., Ltd
  • Beijing SL Pharmaceutical Co., Ltd
  • Harbin Pharmaceutical Group Bioengineering Co., Ltd (商標名:Paclitaxel Injection)
  • Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd
  • Shandong Lukang Cisen Pharmaceutical Co., Ltd
  • Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd (商標名:Paclitaxel Liposome for Injection)
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd (商標名:Paclitaxel Injection)
  • Yangtze River Pharmaceutical Group
  • The Department of Cancer, Bristol-Myers Squibb Company (美國) (商標名:Taxol)

第7章 中國國內的Paclitaxel的主要製造商

  • Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd
  • Yangtze River Pharmaceutical Group
  • The Department of Cancer, Bristol-Myers Squibb Company
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd
  • Shandong Lukang Cisen Pharmaceutical Co., Ltd

第8章 中國的Paclitaxel市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506233

When paclitaxel first came into the market, American Food and Drug Administration (FDA) only approved it to be used in the clinical treatment of advanced non-small cell cancer and advanced ovarian cancer. As paclitaxel rapidly becomes popular in the clinic over the next 20 years, at present it is utilized in the treatment of advanced breast carcinoma, prostatic cancer, Kaposi's sarcoma, head and neck cancer, cutaneous carcinoma and some other common malignant tumors. Ever since it came into the market in 1992, paclitaxel, the best-selling phytogenic anticarcinogen, has brought in an accumulated sales value of over USD 20 billion. Before 2000, 90% of the global paclitaxel market was dominated by Bristol-Myers Squibb Company. After the patent of paclitaxel expired, over 100 companies around the world are engaged in the production of the APIs and preparations of paclitaxel.

China is one of the leading countries with diagnoses of cancer. In China 5 million to 6 million new cases of cancer are identified each year. However, the overwhelmingly high price of paclitaxel injection (CNY 1600 for one dose of paclitaxel injection in the past) has constrained its sale in the Chinese market. Therefore, the sale of paclitaxel in China has been poor in the past ten years. However, ever since Jiangsu Heng Rui Medicine Co., Ltd started to produce the APIs and preparations of Docetaxel, the situation of China lagging behind developed countries in the consumption of paclitaxel has changed. Since domestic paclitaxel injection is much cheaper than its imported counterpart, the formerly high-end medicine has truly become affordable to ordinary people. At present the market price for each dose of domestic paclitaxel injection (30mg/5ml) ranges from CNY 285 to CNY 550. Annual sales value of paclitaxel in China has risen from less than CNY 400 million in 2005 to CNY 1,388 million in 2014, and its CAGR during the period of 2005-2014 was 17.3%. According to the market survey of CRI, leading enterprises in China paclitaxel market include Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd, The Department of Cancer, Bristol-Myers Squibb Company (U.S.), American Pharmaceutical Partners and Abraxis BioScience (U.S.), among which Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd took up over half of the market share in 2014

As planted forests of Chinese yew increases, the output of paclitaxel in China is expected to keep growing.

It is estimated that the market size of paclitaxel in China will keep growing in the next few years.

Readers can have access to at least the following information through reading this report:

  • market size of paclitaxel in China
  • competitive landscape of paclitaxel in Chinese market
  • price of paclitaxel produced by different enterprises in China
  • market outlook of paclitaxel in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antineoplastic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Paclitaxel

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Paclitaxel in China

  • 2.1. Patent and Approval Status of Paclitaxel in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Paclitaxel in China, 2010-2014

  • 3.1. Sales Value
  • 3.1. Overall Sales Value
    • 3.1.2. Sales Value By Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume By Regions

4. Survey on Market Share of Major Manufacturers of Paclitaxel in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Different Dosage Forms of Paclitaxel in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Prices of Paclitaxel in Chinese Hospitals in 2014

  • 6.1. Abraxis BioScience, LLC (US) (Trade Name: Abraxane)
  • 6.2. Hospira Australia Pty Ltd (AU)(Trade Name: Anzatax)
  • 6.3. Wellso Pharmaceutical Co., Ltd
  • 6.4. Bejing Union Pharmaceutical Co., Ltd
  • 6.5. Beijing SL Pharmaceutical Co., Ltd
  • 6.6. Harbin Pharmaceutical Group Bioengineering Co., Ltd (Trade Name: Paclitaxel Injection)
  • 6.7. Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd
  • 6.8. Shandong Lukang Cisen Pharmaceutical Co., Ltd
  • 6.9. Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd (Trade Name: Paclitaxel Liposome for Injection)
  • 6.10. Jiangsu Aosaikang Pharmaceutical Co., Ltd (Trade Name: Paclitaxel Injection)
  • 6.11. Yangtze River Pharmaceutical Group
  • 6.12. The Department of Cancer, Bristol-Myers Squibb Company (United States of America) (Trade Name: Taxol)

7. Major Manufacturers of Paclitaxel in Chinese Market, 2010-2014

  • 7.1. Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd
  • 7.2. Yangtze River Pharmaceutical Group
  • 7.3. The Department of Cancer, Bristol-Myers Squibb Company
  • 7.4. Jiangsu Aosaikang Pharmaceutical Co., Ltd
  • 7.5. Shandong Lukang Cisen Pharmaceutical Co., Ltd

8. Market Outlook of Paclitaxel in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Paclitaxel in China
  • Chart Approval Information of Paclitaxel in China
  • Chart Sales Status of Paclitaxel in Chinese Market, 2010-2014
  • Chart Sales Value of Paclitaxel in China, 2010-2014
  • Chart Sales Value of Paclitaxel in Some Regions of China, 2010-2014
  • Chart Sales Volume of Paclitaxel in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Paclitaxel for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Paclitaxel Produced by Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd in China, 2010-2014
  • Chart Sales Value and Market Share of Paclitaxel Produced by The Department of Cancer, Bristol-Myers Squibb Company in China, 2010-2014
  • Chart Sales Value and Market Share of Paclitaxel Produced by American Pharmaceutical Partners in China, 2010-2014
  • Chart Sales Value and Market Share of Paclitaxel Produced by Abraxis BioScience(US) in China, 2010-2014
  • Chart Sales Value and Market Share of Paclitaxel Produced by Yangtze River Pharmaceutical Group in China, 2010-2014
  • Chart Price of Paclitaxel Produced by Abraxis BioScience, LLC (US) in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Hospira Australia Pty Ltd (AU) in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Wellso Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Bejing Union Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Beijing SL Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Harbin Pharmaceutical Group Bioengineering Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Serum Albumin Produced by Shandong Lukang Cisen Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Nanjing Luye Pharma Group Sike Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Nanjing Jiangsu Aosaikang Pharmaceutical Co., Ltd in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by Yangtze River Pharmaceutical Group in Some Cities of China in 2014
  • Chart Price of Paclitaxel Produced by The Department of Cancer, Bristol-Myers Squibb Company in Some Cities of China in 2014
Back to Top